Validations: URS/Interfaces & Master Data Flows
KPIs for Interface Health and Data Completeness Introduction to Serialization and Aggregation In the pharmaceutical industry, ensuring data integrity is of paramount importance, particularly in serialization and aggregation processes. These processes are essential for compliance with stringent regulations such as the Drug Supply Chain Security Act (DSCSA) in the United States and the European Falsified Medicines Directive (EU FMD) in…
Data Integrity Controls in Interfaces: ALCOA+ Data Integrity Controls in Interfaces: ALCOA+ Introduction to Data Integrity in Pharmaceutical Interfaces Data integrity is a vital component of pharmaceutical operations, particularly in the context of serialization, aggregation, and supply-chain management. With increasing regulatory scrutiny from bodies such as the FDA, EMA, and MHRA, ensuring data integrity across various systems is not only…
Onboarding New Partners: Playbook & Checklists Onboarding New Partners: Playbook & Checklists Introduction to Onboarding in Pharmaceutical Serialization The onboarding process for new partners in pharmaceutical serialization and aggregation is a critical step that ensures compliance with regulations such as the DSCSA in the U.S. and the EU FMD requirements. Proper onboarding establishes a strong foundation for master data governance,…
Data Dictionary for Serialization Programs The pharmaceutical industry is in a constant state of evolution, with regulations and guidelines necessitating robust serialization and aggregation systems. This comprehensive guide will navigate professionals through the creation and implementation of a Data Dictionary for Serialization Programs, ensuring compliance with master data governance and regulatory expectations under the US FDA, EMA, and other global…
Templates: URS & Interface Specification Shells The implementation of Serialization and Aggregation technologies in the pharmaceutical industry is critical for ensuring compliance with regulations such as the Drug Supply Chain Security Act (DSCSA) in the United States and the European Falsified Medicines Directive (FMD) in Europe. This article serves as a comprehensive step-by-step tutorial for pharmaceutical professionals involved in the…
Inspection Storyboards for Interfaces Inspection Storyboards for Interfaces The pharmaceutical industry endures a constantly evolving landscape, particularly regarding serialization and aggregation practices. These protocols are vital for ensuring compliance with regulatory requirements and maintaining robust master data governance. This article serves as a comprehensive, step-by-step tutorial on creating effective inspection storyboards tailored to interfaces within serialization systems. Throughout this guide,…
EPCIS 1.2 vs 2.0: What Changes in Practice EPCIS 1.2 vs 2.0: What Changes in Practice As the pharmaceutical industry continually adapts to evolving regulations and technologies, the Electronic Product Code Information Services (EPCIS) plays a transformative role in maintaining the integrity of supply chains. The transition from EPCIS 1.2 to 2.0 introduces significant changes that influence various aspects of…
Cloud/SaaS Vendors: Shared Responsibility Models Understanding the Shared Responsibility Model in Cloud/SaaS Environments In the modern pharmaceutical landscape, cloud computing and Software-as-a-Service (SaaS) models offer innovative approaches to data management and regulatory compliance. However, governance and compliance responsibilities can become complex when handling sensitive data, particularly related to serialization and aggregation for supply chain integrity. Under the US FDA’s Drug…
Traceability into WMS/TMS: Handshakes That Work Traceability into WMS/TMS: Handshakes That Work Introduction to Traceability in Serialization and Aggregation In the current climate of stringent regulatory demands, ensuring proper traceability throughout the pharmaceutical supply chain is paramount. With initiatives such as the Drug Supply Chain Security Act (DSCSA) in the United States and the EU Falsified Medicines Directive (FMD) in…
Inbound Aggregation from CMOs: Parity and Exceptions Inbound Aggregation from CMOs: Parity and Exceptions Introduction to Inbound Aggregation in Pharmaceutical Manufacturing The pharmaceutical industry faces continuous pressure to ensure product integrity and compliance throughout its supply chain. One critical aspect of this is inbound aggregation from Contract Manufacturing Organizations (CMOs). This process directly impacts serialization and drug supply chain integrity,…